Müller Mareike, Jäkel Lieke, Bruinsma Ilona B, Claassen Jurgen A, Kuiperij H Bea, Verbeek Marcel M
Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Laboratory Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Mol Neurobiol. 2016 Jul;53(5):2894-2899. doi: 10.1007/s12035-015-9156-8. Epub 2015 Apr 21.
The identification of reliable biomarkers for Alzheimer's disease (AD) remains challenging. Recently, abnormal levels of microRNAs (miRNAs) miR-27a, miR-29a, miR-29b, and miR-125b in cerebrospinal fluid (CSF) of AD patients were reported. We aimed to confirm the biomarker potential of these miRNAs for AD diagnosis. Additionally, we examined the influence of blood contamination on CSF miRNA levels as potential confounding factor. We studied expression levels of the four miRNAs by quantitative PCR in CSF samples of AD patients and non-demented controls, and in blood-spiked CSF. Levels of miR-29a, but not of the other three miRNAs, were increased by a factor of 2.2 in CSF of AD patients. Spiking of small amounts of blood into CSF revealed that miR-27a and miR-29a, but not miR-125b levels were strongly influenced by the number of blood cells in the sample. In conclusion, miR-29a may be a candidate biomarker for AD, but only when used in cell-free CSF.
确定阿尔茨海默病（AD）可靠的生物标志物仍然具有挑战性。最近，有报道称AD患者脑脊液（CSF）中微小RNA（miRNA）miR-27a、miR-29a、miR-29b和miR-125b水平异常。我们旨在确认这些miRNA作为AD诊断生物标志物的潜力。此外，我们研究了血液污染作为潜在混杂因素对CSF miRNA水平的影响。我们通过定量PCR研究了AD患者和非痴呆对照的CSF样本以及加有血液的CSF中这四种miRNA的表达水平。AD患者CSF中miR-29a水平升高了2.2倍，而其他三种miRNA水平未升高。向CSF中加入少量血液显示，样本中的血细胞数量对miR-27a和miR-29a水平有强烈影响，但对miR-125b水平无影响。总之，miR-29a可能是AD的候选生物标志物，但仅在用于无细胞CSF时适用。
